AIR-CF1: Disease Severity Clinical Data

At Day 28, placebo-adjusted treatment effect in FEV1 (L) was seen in patients regardless of baseline lung function (FEV1 >50% to ≤75% or FEV1 ≥25% to ≤50% predicted)4

Click here for study design for both subgroups

CAYSTON AIR-CF1: Disease Severity
  • At Day 28, there was a treatment effect of 10.3% (95% CI: 3%, 18%; p=0.0061) in patients with FEV1 ≥25% to ≤50%
  • At Day 28, there was a treatment effect of 10.1% (95% CI: 5%, 15%; p<0.0001) in patients with FEV1 >50% to ≤75%
  • Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups continued but decreased to 6% (95% CI: 2%, 9%)
Learn About Adult/Pediatric Improvements in Respiratory Symptoms
NEXT